Personalized Melanoma Vaccine Breakthrough
Merck and Moderna Report Positive Phase 3 Results for Personalized Melanoma Vaccine
Key Points
In market reaction, Merck's stock rose over 1% in premarket trading and Moderna's stock jumped more than 10% following the Phase 3 melanoma vaccine results.
This trial is described by reporters as the first randomized Phase 3 study to demonstrate a benefit for a neoantigen cancer vaccine, signaling a potential new era in oncology.
Intismeran autogene is highly personalized and is designed to train the immune system to target up to 34 different tumor targets in a given patient’s melanoma.
The vaccine is also known by development aliases V940 and mRNA-4157.
Moderna previously sought accelerated FDA approval for intismeran in 2024, but the FDA declined to fast-track the program at that time.
Merck and Moderna have reported the first positive Phase 3 results ever recorded for a neoantigen cancer vaccine. Their personalized mRNA shot, intismeran autogene, cut the risk of melanoma returning or spreading when combined with Merck's immunotherapy drug Keytruda, according to Ynet News.
Moderna's stock jumped more than 10% in premarket trading on the news. Merck's shares rose over 1%, according to MarketWatch. The trial enrolled about 1,100 patients and showed statistically meaningful improvements in both recurrence-free survival and reduced risk of distant spread.
First Phase 3 Win Ever for a Neoantigen Vaccine
The trial is called INTerpath-001. It compared Keytruda alone against Keytruda plus intismeran in patients with high-risk melanoma that had been surgically removed. The combination won on two key measures: how long patients stayed cancer-free and how long until the cancer spread to distant parts of the body, according to Grafa.
Reporters and analysts called this a landmark moment. Ynet News described it as the first randomized Phase 3 study to show a benefit for any neoantigen cancer vaccine. That makes it a potential turning point for the entire field of personalized cancer treatment.
How the Vaccine Is Built for Each Patient
Intismeran is not a standard shot. It is custom-made for each patient using mRNA technology — the same platform behind some COVID-19 vaccines. Doctors sequence the patient's tumor to find unique mutations. The vaccine is then built to target up to 34 of those specific targets, training the immune system to attack the cancer.
The drug goes by two other names in development: V940 and mRNA-4157. It works alongside Keytruda, an immune checkpoint inhibitor that stops cancer cells from hiding from the immune system. Together, the two drugs hit melanoma from different angles, according to The Globe and Mail.
FDA Rejected Fast-Track Before; Regulatory Path Now Unclear
This is not Moderna's first attempt at fast approval. The FDA declined to grant intismeran accelerated approval in 2024, according to Ynet News. That setback slowed the program. But with Phase 3 data now in hand, both companies said they plan to engage regulators about filing for approval.
Both Merck and Moderna also said they will present the full data at an international medical meeting. No date was given. The combination was described as well tolerated, with no new safety concerns flagged in the trial, according to Investing.com.
What This Means for mRNA Cancer Treatment
mRNA technology has transformed vaccines since COVID-19. But using it to fight cancer has been harder to prove. This Phase 3 result is the strongest evidence yet that the approach works in a real clinical setting. Analysts called it a signal of a new era for personalized oncology.
The next step is regulatory submission. If approved, intismeran would be the first personalized mRNA cancer vaccine on the market. It would also broaden the use of Keytruda, already one of the world's top-selling cancer drugs, into a new combination therapy, according to The Globe and Mail.
Sentiment
Mostly PositivePublishers
130
Articles
460
Reach
590
